Logo

UBS Upgrades Bruker BioSciences After Firm Announces Plan to Buy Bruker Optics

Apr 20, 2006

NEW YORK, April 20 (GenomeWeb News) - UBS today upgraded its assessment of Bruker BioSciences to "Buy" from "Neutral," two days after Bruker announced plans to purchase privately held Bruker Optics.

As GenomeWeb News reported on Tuesday, Bruker said it plans to pay $135 million for Bruker Optics, which makes molecular spectroscopy platforms, the companies said this week.

The acquisition will enable Bruker BioSciences to sell mass spectrometry, X-ray-analysis, and now molecular spectroscopy platforms for proteomics as well as chemical and materials analysis, Bruker said.

Breaking News
The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.